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Abstract 
The aim of the present study was to compare the clinical utility of two measures of the 
inflammatory cell infiltrate - a H&E-based assessment of the generalised inflammatory cell 
infiltrate (the Klintrup-Mäkinen (KM) grade), and an immunohistochemistry-based 
assessment of combined CD3+ and CD8+ T-cell density (the “Immunoscore”), in conjunction 
with assessment of the tumor stroma percentage (TSP) in patients undergoing resection of 
stage I-III colorectal cancer (CRC). 246 patients were identified from a prospectively 
maintained database of CRC resections in a single surgical unit. Assessment of KM grade 
and TSP was performed using full H&E sections. CD3+ and CD8+ T-cell density was 
assessed on full sections and the Immunoscore calculated. KM grade and Immunoscore were 
strongly associated (P<0.001). KM grade stratified cancer-specific survival (CSS) from 88% 
to 66% (P=0.002) and Immunoscore from 93% to 61% (P<0.001). Immunoscore further 
stratified survival of patients independent of KM grade from 94% (high KM, Im4) to 60% 
(low KM, Im0/1). Furthermore, TSP stratified survival of patients with a weak inflammatory 
cell infiltrate (low KM: from 75% to 47%; Im0/1: from 71% to 38%, both P<0.001) but not 
those with a strong inflammatory infiltrate. On multivariate analysis, only Immunoscore (HR 
0.44, P<0.001) and TSP (HR 2.04, P<0.001) were independently associated with CSS. These 
results suggest that the prognostic value of an immunohistochemistry-based assessment of the 
inflammatory cell infiltrate is superior to H&E-based assessment in patients undergoing 
resection of stage I-III CRC. Furthermore, assessment of the tumor-associated stroma, using 
TSP, further improves prediction of outcome.  
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Introduction 
 Colorectal cancer is the second most common cause of cancer death in the United 
Kingdom and Europe.1  Following potentially curative surgery, prognosis and the need for 
adjuvant therapy is primarily based on pathological assessment of the depth of invasion of the 
primary tumor and the presence of lymphatic and distant organ metastases.2  However, this 
TNM-based staging may fail to accurately stage all patients, and in particular those with 
earlier stage, lymph node negative disease, where other tumor characteristics may identify 
patients at increased risk and who may benefit from adjuvant treatment.  
 In addition to such tumor-based characteristics, assessment of the tumor 
microenvironment may similarly inform prognosis. For example, it is now accepted that the 
host local inflammatory response is an important determinant of disease progression and 
oncological outcome in patients with colorectal cancer, with the presence of a conspicuous 
inflammatory cell infiltrate identified as an independent predictor of improved survival.3, 4  
Although semi-quantitative, histopathological assessment of the density of the generalised 
inflammatory cell infiltrate using routine pathological specimens has been validated as a 
stage-independent prognostic characteristic,5, 6 the prognostic value of 
immunohistochemistry-based assessment of immune cell type and location within the tumor 
microenvironment, such as the Immunoscore, has been of interest.7, 8  Although initially 
describing the density of cytotoxic (CD8+) and memory (CD45R0+) T-lymphocytes within 
the tumor microenvironment, the Immunoscore has recently been refined to reflect a 
cumulative score based on the density of the overall mature CD3+ T-lymphocyte population 
in addition to the CD8+ T-lymphocyte population within the tumor invasive margin and 
tumor core, and has been validated as a prognostic marker with superior prognostic ability 
compared to TNM staging in colorectal cancer.8-10  However, whether the Immunoscore is 
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superior to the Klintrup-Mäkinen (KM) assessment of the generalised inflammatory cell 
infiltrate remains to be determined. 
Together with the inflammatory cell infiltrate, the tumor-associated stroma has also 
been characterised as an important determinant of disease progression in colorectal cancer.11  
In particular, assessment of the proportion of stroma, or tumor stroma percentage (TSP), 
within the tumor microenvironment has been shown to predict survival independent of TNM 
stage for patients undergoing potentially curative resection of colorectal cancer as well as 
other cancers.12-16  Furthermore, in patients with colorectal cancer, TSP has been shown to 
hold prognostic value independent of the inflammatory cell infiltrate as assessed using the 
KM grade.13  Indeed, combined assessment of KM grade and TSP, termed the Glasgow 
Microenvironment Score (GMS), stratified survival greater than either measure alone, and in 
particular further stratified survival of those patients with a weak local inflammatory cell 
infiltrate.17  However, whether inclusion of a potentially more detailed measure of the 
inflammatory cell infiltrate, such as the Immunoscore, may alter the prognostic value of the 
tumor-associated stroma is not clear. Therefore, the present study of patients undergoing 
potentially curative resection of stage I-III colorectal cancer has two aims: to compare the 
prognostic value of assessment of the inflammatory cell infiltrate using the KM grade and the 
Immunoscore, and to examine the clinical utility of combined assessment of the 
inflammatory cell infiltrate and TSP. 
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Patients and Methods 
Patients and clinicopathological characteristics 
 Patients were identified from a prospectively collected database of all elective and 
emergency colorectal cancer resections performed in a single surgical unit in Glasgow Royal 
Infirmary since 1997. For the purposes of the present study, patients who had undergone 
primary resection between 1997 and 2008 for stage I-III colorectal cancer were included. 
Patients who had undergone localised or endoscopic resection, surgery with palliative intent, 
neoadjuvant chemoradiotherapy or who had died within 30 days of surgery were excluded. 
Only patients with rectal cancer who, after discussion at local colorectal multidisciplinary 
meetings comprised of colorectal surgeons, pathologists, radiologists and oncologists, were 
deemed to not require neo-adjuvant therapy prior to curative surgery were included. Approval 
was obtained from the West of Scotland Ethics Committee. 
 Pathological staging was performed according to the TNM 5th edition.2  Venous 
invasion was identified using elastica staining as has been routine in our department since 
2003; patients who had undergone resection prior to 2003 underwent retrospective reporting 
of venous invasion with elastica staining. Patients were routinely discussed at local colorectal 
cancer multidisciplinary meetings following resection; patients with stage III disease or high-
risk stage II disease were considered for adjuvant chemotherapy when not precluded by 
advanced age, significant co-morbidity, or patient preference. Use of anti-angiogenic and 
anti-EGFR inhibitors was not routine during the study period. 
 The systemic inflammatory response, a stage-independent predictor of survival in 
patients with colorectal cancer, was reported using the modified Glasgow Prognostic Score 
(mGPS) as previously described.18  Briefly, patients with serum C-reactive protein (CRP) ≤ 
10mg/L were given a score of 0, patients with CRP> 10mg/L and serum albumin≥ 35g/L a 
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score of 1, and patients with CRP> 10mg/L and albumin < 35g/L a score of 2. Serum CRP 
and albumin were recorded within 30 days prior to surgery for patients undergoing elective 
resection and on admission for patients undergoing emergency resection. 
Assessment of the tumor microenvironment 
 The generalised inflammatory cell infiltrate was assessed using the KM score as 
previously described.6  Briefly, haematoxylin and eosin-stained (H&E) section of the deepest 
point of tumor invasion were retrieved and the generalised inflammatory cell infiltrate at the 
invasive margin assessed in a semi-quantitative fashion using a four-point scale (0- no 
increase, 1- mild or patchy increase in inflammatory cells, 2- prominent inflammatory 
reaction forming a band at the invasive margin, and 3- florid cup-like infiltrate at the invasive 
edge with destruction of cancer cell islands). For the purposes of statistical analysis, patients 
were subsequently classified as low grade (0/1) or high grade (2/3) response (Figure 1a-b). 
 Full sections of the invasive margin were stained using antibodies for CD3+, a mature 
T-lymphocyte marker, and CD8+, a marker of cytotoxic T-lymphocytes, as previously 
described.19  The Immunoscore was then calculated as previously described.8, 19  Briefly, the 
density of CD3+ and CD8+ T-cells within the invasive margin and tumor centre were 
separately semi-quantitatively graded as high or low; the Immunoscore was calculated from 
the number of regions with a high CD3+ and CD8+ cell density, giving five potential groups 
(Im0, Im1, Im2, Im3, Im4), ranging from all regions low density (Im0) to all regions high 
density (Im4). 
 Tumor stroma percentage was examined as previously described.13  Briefly, using 
H&E sections of the invasive margin, TSP was calculated as the percentage of the visible 
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field comprised of stroma, excluding areas of necrosis and mucin deposition. Patients were 
graded as either low (≤50%) or high TSP (>50%) (Figure 1c-d). 
 All assessments of the tumor microenvironment were performed by a single 
investigator blinded to clinical outcomes with co-scoring of at least 10% to ensure 
consistency of scoring. As previously reported, the intra-class correlation coefficient was 
greater than 0.8 for all assessments, indicating excellent agreement (KM grade – 0.81; TSP -
0.81; CD3+ margin – 0.83; CD3+ centre – 0.87; CD8+ margin – 0.83; CD8+ centre – 0.87) 6, 13, 
19 
 Survival 
 Following resection patients were routinely followed-up for five years according to 
local treatment and surveillance guidelines. Date and cause of death were crosschecked with 
the cancer registration system and the Registrar General (Scotland). Cancer-specific survival 
was measured in months as the date from surgery until date of death from recurrent or 
metastatic colorectal cancer. Death records were complete until March 31, 2014, which acted 
as the censor date. 
Statistical analysis 
 The relationship between components of the tumor microenvironment and cancer-
specific survival was examined using Kaplan-Meier log-rank analysis, with five-year survival 
presented as percentage surviving (standard error). The relationship between components of 
the tumor microenvironment, clinicopathological characteristic and survival was examined 
using multivariate Cox proportional hazards regression to calculate hazard ratios (HR) and 
95% confidence intervals (CI). Variables with a P-value ≤0.05 on univariate regression 
analysis were entered into a multivariate model using a backward conditional approach. All 
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statistical analyses were performed using SPSS version 22.0 (IBM SPSS). A P-value ≤0.05 
was considered statistically significant.  
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Results 
 The study population was comprised of 246 patients undergoing potentially curative 
resection of stage I-III colorectal cancer. Clinicopathological characteristics are displayed in 
Table 1. Approximately two thirds of patients were 65 years of age or older at time of surgery 
and 52% were male. Fifteen patients (6%) underwent emergency resection, and just over two 
thirds of patients underwent resection of colon cancer. Histopathological reporting confirmed 
stage I, stage II and stage III disease in 7%, 52% and 41% of patients respectively. Mismatch 
repair status has previously been reported in a subset of this cohort and was available for 205 
patients;17 30 patients (15%) had mismatch repair deficient colorectal cancer.  
The mean follow-up of survivors was 150 months (range 87-206 months) with 76 
colorectal cancer-related deaths and 76 non-cancer deaths. Mean and five-year survival was 
40 months and 74% for cancer-specific survival, and 79 months and 63% for overall survival. 
In total, 71 patients (29%) received adjuvant chemotherapy; one patient with stage I (6%) 
disease, 19 patients with stage II disease (15%), and 51 patients with stage III disease (51%) 
received adjuvant chemotherapy. Compared to patients who did not receive adjuvant therapy, 
patients with node negative (stage I/II) disease who received adjuvant chemotherapy were 
younger (P=0.004), more likely to have venous invasion (P=0.009), margin involvement 
(P=0.045) or peritoneal involvement (P=0.046) and showed a trend towards emergency 
presentation (P=0.078) and poor tumor differentiation (P=0.062). Patients receiving adjuvant 
chemotherapy showed a non-significant trend towards poorer survival (P=0.158); patients 
with node negative (stage I/II) disease receiving adjuvant therapy showed a trend towards 
poorer five-year survival (69% vs. 85%; P=0.196), whereas patients with node positive (stage 
III) disease receiving adjuvant therapy showed a trend towards increased five-year survival 
(69% vs. 51%; P=0.153). 
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Relationship between local inflammatory cell infiltrate and cancer-specific 
survival 
 The relationship between the inflammatory cell infiltrate and cancer-specific survival 
is displayed in Figure 2. The KM score was associated with cancer-specific survival 
(P=0.015; Figure 1a). When classified as low grade or high grade, a low KM grade was 
associated with poorer five-year survival (66% vs. 88%; P=0.002; Figure 1b). When stratified 
by tumor site (Supplementary Table 1, Supplementary Figure 1), low KM grade was 
associated with poorer survival in patients with colon cancer (P<0.05) and showed a trend 
towards poorer survival in patients with rectal cancer (P=0.068). When stratified by TNM 
stage, low KM grade showed a trend towards poorer survival in patients with node negative 
(TNM I/II) disease (P=0.053) and node positive (TNM III) disease (P=0.057). Finally, low 
KM grade was associated with poorer survival in both patients who did not received and who 
received adjuvant chemotherapy (both P<0.05). 
A decrease in Immunoscore was associated with a decrease in cancer-specific survival 
(Figure 1c): five-year cancer-specific survival ranged from 93% for patients with an 
Immunoscore=4 to 61% for patients with an Immunoscore=0 (P<0.001). The survival of 
patients with Im0 and Im1, or Im2 and Im3 did not differ significantly (P=0.788 and 
P=0.599, respectively). As such, for further statistical analysis the Immunoscore was refined 
to stratify patients in to three prognostic groups (Figure 1d): Im4, with five-year survival of 
93%; Im2/3, with five-year survival of 84%; and Im0/1, five-year survival of 61% (P<0.001). 
When stratified by tumor site or TNM stage (Supplementary Table 1, Supplementary Figure 
2), the Immunoscore was associated with survival of patients with both colon and rectal 
cancer (both P<0.01) and of patients with both node negative (P<0.01) and node positive 
(P<0.05) disease. Finally, low Immunoscore was associated with poorer survival in patients 
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who did not receive adjuvant chemotherapy (P<0.001) and showed a trend towards poorer 
survival in patients who did receive adjuvant therapy (P=0.059). 
The KM grade was strongly associated with the Immunoscore (P<0.001; Figure 3), 
however neither KM grade nor Immunoscore were associated with mismatch repair status 
(P=0.661 and P=0.284 respectively) or the systemic inflammatory response as measured by 
mGPS (P=0.999 and P=0.214 respectively). .Comparison between the prognostic value of the 
KM grade and Immunoscore was subsequently performed (Table 2). The KM grade stratified 
five-year cancer-specific survival from 88% (high grade) to 66% and the Immunoscore 
stratified survival from 93% to 61%. The Immunoscore was able to further stratify the 
survival of patients with both a low and high KM grade; the survival of patients with a low 
grade KM ranged from 90% (Im4) to 60% (Im0/1) (P=0.015), whereas the survival of 
patients with a high grade KM ranged from 94% (Im4) to 71% (Im0/1) (P=0.010). In 
contrast, the KM grade did not further significantly stratify the Immunoscore. 
Relationship between tumor stroma percentage, the tumor inflammatory cell 
infiltrate and cancer-specific survival 
The prognostic value of combined assessment of the inflammatory cell infiltrate and 
TSP was subsequently examined (Table 3). The TSP significantly stratified the survival of 
patients from 80% (low TSP) to 57% (high TSP) (P=0.001). In combination with the 
inflammatory cell infiltrate, TSP significantly stratified survival of those with a weak 
infiltrate but not those with a strong infiltrate. In particular, TSP significantly stratified 
survival of patients with a low KM grade from 75% to 47% (P<0.001), whereas in patients 
with a high KM grade, survival of patients with a low TSP was comparable to that of patients 
with a high TSP (P=0.485). In combination with the Immunoscore, the effect of TSP on 
survival decreased as the Immunoscore increased; TSP stratified the survival of patients with 
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Im0/1 from 71% to 38% (P<0.001) and patients with Im2/3 from 87% to 77% (P=0.069), but 
not patients with Im4 (P=0.545) (Figure 4). Conversely, assessment of the inflammatory cell 
infiltrate was able to stratify survival of patients with both a high and low TSP; KM grade 
stratified patients with a low TSP from 88% to 75% (P=0.081) and patients with a high TSP 
from 87% to 47% (P=0.034), whereas Immunoscore stratified survival of patients with a low 
TSP from 92% to 71% (P=0.002) and patients with a high TSP from 100% to 38% 
(P=0.004). 
Relationship between the tumor microenvironment, clinicopathological 
characteristics and cancer-specific survival 
On univariate survival analysis (Table 4), emergency presentation, T stage, mGPS 
(both P<0.05), N stage, venous invasion, margin involvement and peritoneal involvement (all 
P≤0.001) were associated with cancer-specific survival. The KM grade (P=0.003), 
Immunoscore and TSP were all associated with survival (both P<0.001). 
 On multivariate analysis, after controlling for age, sex, tumor site and adjuvant 
therapy and considering all variables significant on univariate analysis, the Immunoscore and 
TSP (both P<0.01), but not the KM grade, were associated with survival independent of 
venous invasion (P=0.001) and mGPS (P<0.05). When the Immunoscore was removed from 
the multivariable model, KM grade (P<0.05) and TSP (P<0.01) remained associated with 
survival independent of venous invasion (P=0.001) and mGPS (P<0.01). 
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Discussion 
 In the present study, an immunohistochemistry-based assessment of the inflammatory 
cell infiltrate was superior to that of H&E-based assessment in predicting outcome of patients 
undergoing potentially curative resection of stage I-III colorectal cancer. Furthermore, the 
combination of assessment of the inflammatory cell infiltrate, using either KM grade or 
Immunoscore, and assessment of the tumor-associated stroma, using TSP, provided 
additional prognostic information. 
 The present study compared the prognostic utility of two validated measures of the 
tumor inflammatory cell infiltrate – the KM grade and the Immunoscore.5, 8 Although both 
were associated with cancer-specific survival, the Immunoscore, an immunohistochemistry-
based assessment of CD3+ and CD8+ T-lymphocyte density, was able to better stratify 
survival of patients than the KM grade, an H&E-based assessment of the generalised 
inflammatory cell infiltrate. In particular, the Immunoscore was able to stratify survival of 
patients with both a low and high KM grade; indeed, survival of patients with a low KM 
grade but high Immunoscore was comparable to that of patients with a high KM grade. 
 The relative difference in the prognostic value of both measures of the inflammatory 
cell infiltrate may be explained by the components of the immune response that each 
measures. Whereas the KM grade provides a measure of the overall, generalised 
inflammatory cell infiltrate, the Immunoscore measures the host adaptive T-lymphocytic 
response to cancer. Indeed, although an increase in KM grade is associated with an increase 
in the density of tumor-infiltrating T-lymphocytes,19-21 it is also associated with an increase in 
the density of the innate immune infiltrate, and in particular neutrophils and macrophages.20, 
21 For example, in the present study, within the group of patients with a high KM grade, the 
number of patients with a low (Im0/1, n=19) or high (Im4, n=21) Immunoscore was similar, 
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whereas of those patients with a low KM grade, a small number had a high Immunoscore. 
However, although the importance of host adaptive anti-tumor immune responses is 
recognised, it is now appreciated that myeloid-derived cells, such as neutrophils and 
macrophages, play an important functional role in promoting tumor progression.22 Indeed, it 
remains to be determined whether immunohistochemical assessment of the innate immune 
infiltrate may increase the clinical and prognostic utility of measuring the inflammatory cell 
infiltrate in patients with colorectal cancer. 
It was of interest in the present cohort that TSP, an assessment of the tumor-
associated stroma, was associated with survival independent of either measure of the 
inflammatory cell infiltrate, and that combined assessment provided greater prognostic value. 
For example, it was possible to stratify five-year survival from 92% (Im4, low TSP) to 38% 
(Im0/1, high TSP). Furthermore, although the relationship between TSP and survival was 
strongest in patients with a poor inflammatory cell infiltrate, both the number of patients with 
a high TSP, and its prognostic value, decreased as the density of the inflammatory infiltrate 
increased. Although it has previously been suggested that the presence of a tumor-associated 
stroma precludes effective infiltration of the tumor microenvironment by an anti-tumor 
immune response,23 the present results are consistent with our previous findings,17 and may 
favour the alternative hypothesis that loss of the adaptive immune infiltrate predisposes to the 
development of a pro-tumor stromal compartment, potentially mediated by the residual innate 
immune infiltrate.21, 24, 25 
We have previously proposed a novel prognostic score based on assessment of the 
KM grade and TSP, termed the Glasgow Microenvironment Score,17 however the present 
results suggest that a similar scheme may be applied to the combination of the Immunoscore 
and TSP and may have even greater clinical utility. Indeed, such a combination may optimise 
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risk prediction in patients undergoing colorectal cancer resection by identifying both those 
with an excellent prognosis (Im4; five-year cancer-specific survival of 93%), and those with 
an extremely poor prognosis who may benefit from adjuvant therapy (Im0/1, high TSP; five-
year cancer-specific survival of 38%).  
In the present study, it was of interest that both the systemic inflammatory response as 
measured by mGPS, and the local inflammatory cell infiltrate as measured by KM grade or 
Immunoscore had independent prognostic value in the multivariate analysis. It is likely that 
these measures reflect the same underlying process and therefore it would be of interest to 
compare the local and systemic inflammatory responses and how they may be combined to 
form a prognostic score. Indeed, Turner and colleagues have recently combined measures of 
the local and systemic inflammatory response to give better risk stratification in patients with 
node negative colorectal cancer 26. However, the rationale of their approach that combined 
the neutrophil: lymphocyte ratio (NLR) and assessment of the chronic inflammatory cell 
density, was not clear since different cell types were assessed locally and systemically. 
Indeed, only approximately 20% of patients had an elevated NLR and a low chronic 
inflammatory cell density, and therefore this score does not capture the same entity. 
Similarly, combinations of other systemic and local inflammatory measures, such as the 
mGPS and KM grade or Immunoscore, will have such limitations. Moreover, the numbers of 
patients included in the present study (n=246) limits the value of such analysis and therefore 
was not formally examined.  
Of note in the present study, the use of adjuvant chemotherapy was not associated 
with a significant improvement in survival and, in patients with node negative disease, 
showed a non-significant trend towards poorer survival. However, given the effect size of 
adjuvant chemotherapy in patients with node negative disease is modest (3.6% absolute 
improvement in survival of patients with stage II disease at five years in the QUASAR trial 
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(n=2983)),27 the present study did not have sufficient statistical power to examine the impact 
of adjuvant chemotherapy on survival of patients with colorectal cancer. 
The present study is perhaps limited by its use of manual, semi-quantitative 
assessment of the inflammatory cell infiltrate as opposed to automated assessment as has 
been recommended for routine assessment of the Immunoscore.8 However, the manual 
techniques employed showed excellent inter-operator agreement6, 19 and manual assessment 
of the inflammatory cell infiltrate has been shown to correlate strongly with automated 
assessment.28, 29 Furthermore, manual assessment of immunohistochemical staining may 
allow for greater discrimination of non-specific, background staining and provide superior 
prognostic value compared to automated assessment.29 Furthermore, meaningful statistical 
analysis was precluded by the small number of patients in particular subgroups, such as those 
with stage II disease and high-risk pathological characteristics, or patients with stage I 
disease.  Finally, the results of the present study, and in particular the prognostic utility of 
combined assessment of the inflammatory cell infiltrate and tumor-associated stroma, remain 
to be validated in an independent patient cohort from an independent centre. 
In conclusion, the present results suggest that the prognostic value of an 
immunohistochemistry-based assessment of the inflammatory cell infiltrate is superior to 
H&E-based assessment in patients undergoing potentially curative resection of stage I-III 
colorectal cancer. Furthermore, TSP improves the prediction of survival by either measure of 
the inflammatory cell infiltrate.  
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Figure Legends 
 
Figure 1. Haematoxylin and eosin-based assessments of the tumor microenvironment of 
patients undergoing potentially curative resection of stage I-III colorectal cancer (a) low 
Klintrup-Mäkinen grade, (b) high Klintrup-Mäkinen grade, (c) low tumor stroma percentage, 
and (d) high tumor stroma percentage (x80 magnification). 
Figure 2. Relationship between tumor inflammatory cell infiltrate and cancer-specific 
survival of patients undergoing potentially curative resection of stage I-III colorectal cancer 
(a) Klintrup-Mäkinen score (P=0.015), (b) Klintrup-Mäkinen grade (P=0.002), (c) 
Immunoscore (P<0.001), and (d) Immunoscore stratified in to three groups (P<0.001). 
Figure 3. Relationship between Klintrup-Mäkinen grade and Immunoscore in patients 
undergoing potentially curative resection of stage I-III colorectal cancer (P<0.001). 
Figure 4. Relationship between Immunoscore, tumor stroma percentage and cancer-specific 
survival in patients undergoing potentially curative resection of stage I-III colorectal cancer 
(a) Im0/1 (P<0.001), (b) Im2/3 (P=0.069), (c) Im4 (P=0.545) 
 






Table 1. Clinicopathological characteristics of 246 patients undergoing 
potentially curative resection of stage I-III colorectal cancer 
 
 N (%) 
Age (<65/ 65-74/ >75) 82 (33) / 84 (34) / 80 (33) 
Sex (female/ male) 117 (48) / 129 (52) 
Presentation (elective/ emergency) 231 (94) / 15 (6) 
Adjuvant therapy (no/ yes) 175 (51) / 71 (29) 
Tumor site (colon/ rectum) 169 (69) / 77 (31) 
TNM stage (I/ II/ III) 18 (7) / 128 (52) / 100 (41) 
T stage (1-2/ 3/ 4) 26 (11) / 152 (62) / 68 (28) 
N stage (0/ 1/ 2) 146 (59) / 77 (31) / 23 (9) 
LN examined (>12/ <12) 159 (65) / 87 (35) 
Differentiation (mod-well/ poor) 216 (88) / 30 (12) 
Venous invasion (no/ yes) 158 (64) / 88 (36) 
Margin involvement (no/ yes) 230 (94) / 16 (7) 
Peritoneal involvement (no/ yes) 178 (72) / 68 (28) 
Tumor perforation (no/ yes) 238 (97) / 8 (3) 
Mismatch repair status (competent/ 
deficient) (205)* 
175 (85) / 30 (15) 
Tumor stroma percentage (low/ high) 179 (73) / 67 (27) 
Klintrup-Mäkinen score (0/ 1/ 2/ 3) 50 (20) / 111 (45) / 64 (26) / 21 (9) 
Klintrup-Mäkinen grade (low/ high) 161 (65) / 75 (35) 
Immunoscore (0/ 1/ 2/ 3/ 4) 87 (35) / 40 (16) / 44 (18) / 43 (18) / 
32 (13) 
Alive/ cancer death/ non-cancer death 94 (38) / 76 (31) / 76 (31) 
 *data not available for 41 patients 
  
 
Table 2 Relationship between Immunoscore, Klintrup-Mäkinen grade 
and cancer-specific survival of patients undergoing potentially curative 
resection of stage I-III colorectal cancer. 
 
 Low grade KM High grade KM All KM 
Immunoscore N 5-yr CSS N 5-yr CSS N 5-yr CSS 
Im0/1 108 60% (5) 19 71% (11) 127 61% (4) 
Im2/3 42 77% (7) 45 91% (4) 87 84% (4) 
Im4 11 90% (9) 21 94% (5) 32 93% (5) 
All (Im0-4) 161 66% (4) a 85 88% (4) a  246 74% (3) 
Survival displayed as five-year cancer-specific survival (standard error) 
a Log-rank survival analysis P<0.05 
KM – Klintrup-Mäkinen, CSS – cancer-specific survival 
 
 
Table 3 Relationship between measures of the local inflammatory cell infiltrate, tumor stroma percentage and cancer-
specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer. 
 
 KM Immunoscore 
 Low grade  High grade All KM Im0/1 Im2/3 Im4 All Immunoscore
TSP N 5-yr CSS  N 5-yr CSS N 5-yr CSS N 5-yr CSS N 5-yr CSS N 5-yr CSS N 5-yr CSS 
High 50 47% (7)  17 87% (9) 67 57% (6) a 37 38% (8) 24 77% (9) 6 100% (0) 67 57% (6) b 
Low  111 75% (4)  68 88% (4) 179 80% (3)  90 71% (5) 63 87% (4) 26 92% (5) 179 80% (3) b 
All  161 66% (4)c   85 88% (4)  246 74% (3) 127 61% (4) c 87 84% (4) 32 93% (5)  246 74% (3) 
Survival displayed as five-year cancer-specific survival (standard error) 
a P<0.05, b P<0.01, c P<0.001. KM- Klintrup-Mäkinen, TSP- tumor stroma percentage, CSS- cancer-specific survival 
 
Table 4 Relationship between the tumor microenvironment, clinicopathological characteristics and cancer-specific survival of patients 
undergoing potentially curative resection of stage I-III colorectal cancer 
 Cancer-specific survival 
 Univariate HR (95% CI) P Multivariate HR (95% CI)
(Model 1) 
P Multivariate HR 
(95% CI) 
(Model 2) 
P 
Age (<65/ 65-74/ >75) 1.18 (0.90-1.57) 0.237 - 0.444 - 0.091 
Sex (female/ male) 0.93 (0.59-1.46) 0.762 - 0.065 - 0.308 
Presentation (elective/ emergency) 2.22 (1.06-4.62) 0.034 - 0.724 - 0.369 
Adjuvant therapy (no/ yes) 1.40 (0.88-2.24) 0.160 - 0.988 - 0.505 
mGPS (0/ 1/ 2) 1.50 (1.10-2.05) 0.010 1.52 (1.09-2.11) 0.013 1.61 (1.16-2.24) 0.005 
Tumor site (colon/ rectum) 0.82 (0.49-1.36) 0.433 - 0.479 - 0.316 
T stage (1-2/ 3/ 4) 1.49 (1.07-2.07) 0.017 - 0.704 - 0.981 
N stage (0/ 1/ 2) 1.78 (1.32-2.41) <0.001 - 0.148 - 0.066 
Lymph nodes examined (>12/ <12) 1.38 (0.87-2.17) 0.171 - - - - 
Differentiation (mod-well/ poor) 1.40 (0.72-2.72) 0.322 - - - - 
Venous invasion (no/ yes) 2.95 (1.87-4.66) <0.001 2.20 (1.37-3.54) 0.001 2.35 (1.45-3.80) 0.001 
Margin involvement (no/ yes) 3.15 (1.56-6.33) 0.001 - 0.067 - 0.096 
Peritoneal involvement (no/ yes) 2.19 (1.38-3.46) 0.001 - 0.225 - 0.125 
Tumor perforation (no/ yes) 2.52 (0.92-6.93) 0.072 - - - 0.060 
MMR status (competent/ deficient) 0.42 (0.17-1.05) 0.064 - - - - 
TSP (low/ high) 2.46 (1.56-3.89) <0.001 2.36 (1.44-3.84) 0.001 2.05 (1.28-3.30) 0.003 
KM grade (weak/ strong) 0.44 (0.25-0.76) 0.003 - 0.469 0.50 (0.29-0.87) 0.015 
Immunoscore (Im0-1/ Im2-3/ Im4) 0.66 (0.56-0.80) <0.001 0.43 (0.28-0.66) <0.001   
mGPS – modified Glasgow Prognostic Score, MMR- mismatch repair status, TSP – tumor stroma percentage, KM – Klintrup-Mäkinen 
 
 
Supplementary table 1. Relationship between components of the tumor microenvironment, tumor site, TNM stage and adjuvant 
chemotherapy use and cancer-specific survival of patients undergoing potentially curative resection of colorectal cancer 
  Tumor site TNM stage Adjuvant therapy
  Colon Rectum TNM I/II TNM III No adjuvant therapy Adjuvant therapy 
  5yr CSS P 5yr CSS P 5yr CSS P 5yr CSS P 5yr CSS P 5yr CSS P
KM grade Low 65% (5) 0.018 69% (7) 0.068 77% (5) 0.053 53% (6) 0.057 69% (5) 0.028 61% (7) 0.046
 High 88% (4) 88% (6) 93% (4) 78% (8) 87% (4) 89% (7)
Immunoscore Im 0/1 63% (5) 0.003 58% (8) 0.001 72% (6) 0.002 49% (7) 0.011 62% (5) <0.001 59% (8) 0.059
 Im 2/3 81% (5) 92% (5) 92% (4) 72% (8) 89% (4) 74% (8)
 Im 4 90% (7) 100% (0) 95% (5) 88% (12) 91% (6) 100% (0)
TSP High  51% (8) <0.001 67% (10) 0.102 73% (9) 0.073 45% (8) 0.007 62% (8) 0.005 52% (9) 0.016
 Low  80% (4) 80% (6) 85% (3) 70% (6) 79% (4) 82% (6)
Survival displayed as five-year cancer-specific survival/% (standard error) 
KM- Klintrup-Mäkinen, TSP- tumor stroma percentage, CSS- cancer-specific survival 
 
